Replies to post #103432 on Biotech Values

[y3maxx]

Dew,

With respect, this is no longer about the science nor about Teva's potential generic as competition.

M enox sales are a given.

This is about "Business".

MNTA is effectively trading equivalent or less than before FDA approval regarding an established blockbuster.

Wheeler is getting clocked and his 10b_5 plan sale of 2019 shares last week does not make sense to me.

That was a nickel and dime move, or it was something else.

jmo

y3